To elucidate the mechanism by which bcl-2 affects apoptosis in post-th
ymic T cells, we investigated the expression of Bcl-2 protein in prima
ry cultures of splenic T cells and in the interleukin-2 (IL-2)-depende
nt T-cell line CTLL-2. The overall level of Bcl-2 was determined by im
munoblotting, and the variability in Bcl-2 expression was determined b
y flow cytometry. For a few days after concanavalin A (Con A) plus IL-
2 activation, the overall level of Bcl-2 in T cells remains unchanged,
but it becomes more heterogeneous. By 5 days after activation, the ex
pression returns to a more homogeneous distribution, but it is increas
ed up to threefold above pre-activation levels, depending upon the dos
e of IL-2 supplied. When Con A blasts or CTLL-2 cells are deprived of
IL-2 for 34 hr, there is no change in their overall Bcl-2 levels which
remain homogeneous even though almost half of the cells are apoptotic
. However, when bcl-2 transfected CTLL-2 cells are deprived of IL-2, t
hey do not undergo apoptosis, and their endogenous Bcl-2 protein level
slowly decreases relative to their total protein. These data document
the IL-2-dependent expression of Bcl-2 in activated T cells, confirm
the ability of deregulated bcl-2 to inhibit the onset of apoptosis aft
er IL-2 withdrawal, but suggest that, after IL-2 withdrawal, a drop in
Bcl-2 levels relative to total protein levels does not precede apopto
sis.